Onco Actu du 9 juin 2017

	3.3 Prévention - Vaccins
Calls strengthen for HPV vaccine for boys [Pharmafile] Many countries around the world already immunise boys, including the US, Canada and Australia, and the WHO recommends that all countries that can afford it do the same. The UK’s position, as the fifth largest economy, then stands as an anomaly and counter to guidance.
	3.5 Prévention - UV
Tanning bed use declining among U.S. adults [Reuters] In 2010, 5.5 percent of survey participants used indoor tanning, which dropped to 3.5 percent in 2015.
	4.9 Dép., diag. & prono. - Sein
With Breast Cancer, the Best Treatment May Be No Treatment [Wired] “For 100 years we thought that small cancers had a better prognosis because we caught them earlier,” says surgeon and study co-author Donald Lannin. “But it turns out small cancers have better outcomes because they’re fundamentally different in their composition."
	5.12 Immunothérapies
Study Adds Evidence That Flaws in a Tumor's Genetic Mending Kit Drive Treatment Response to Immunotherapy Drugs [Johns Hopkins] In an expanded, three-year clinical trial of 86 patients with colorectal and 11 other kinds of cancer that have so-called ‘mismatch repair’ genetic defects, scientists at Johns Hopkins Medicine and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have found that half of the patients respond to an immunotherapy drug called pembrolizumab (Keytruda).
Certain genetic faults could help predict success of immunotherapy [Cancer Research UK] The researchers looked at the genes in patients’ tumours. They found that the patients who responded to this treatment all had cancers with defects in a set of genes called mismatch repair genes.
Cancer Drug Proves to Be Effective Against Multiple Tumors [NY Times] Just 4 percent of cancer patients have the type of genetic aberration susceptible to pembrolizumab. But that adds up to a lot of patients: as many as 60,000 each year in the United States alone, the study’s investigators estimated.
	5.12.3 Immunothérapies-combinaisons
Combining immunotherapies could benefit some aggressive breast cancers [Cancer Research UK] Looking at mice with this type of breast cancer, the researchers found that using molecules to block two different checkpoints, combined with a chemotherapy drug, boosted the animals’ immune response against the tumour. This approach also slowed down their tumour growth and improved survival.
	5.2.1 Pharma - Partenariats
Roche ditches work on NewLink’s IDO cancer candidate [FierceBiotech] The finding cast serious doubts on the future of the company's HyperAcute platform cancer vaccine platform, which was subsequently parked by the company as it focused on its IDO inhibitor candidates.
Why Did This IDO Inhibitor Trial Fail? [In the Pipeline] This combination was already in the clinic by the time the paper appeared, with a fair amount of optimism from observers. But we now have a readout on how it’s going, and the answer is “not well”.
	5.5 ASCO
ASCO and Foundation Medicine Announce Collaboration to Help Research Sites Identify Potential Participants for the Targeted Agent and Profiling Utilization (TAPUR) Study [ASCO] As part of this pilot program, Foundation Medicine will use its SmartTrials™ technology to create reports for TAPUR sites that identify patients who may qualify to participate in the TAPUR Study.
Caris Life Sciences’ Molecular Intelligence Reports Optimized for the American Society of Clinical Oncology, Inc. TAPUR Study [ASCO] Caris Molecular Intelligence, which has performed more than 117,000 clinical cases to date and helps physicians and researchers more effectively evaluate therapy options and clinical trial opportunities, meets the TAPUR Study’s established requirements for optimized reporting.
	5.5.8 ASCO (poumon)
ASCO 2017: What You Need to Know [Lung Cancer Alliance] An important theme in the meeting was that molecular testing is critical for patients with non-small cell lung cancer (NSCLC) – it can help direct your therapy choices as well as which clinical research studies may be a good choice for you.
	6. Lutte contre les cancers
NIH abandons controversial plan to cap grants to big labs, creates new fund for younger scientists [Science] The new plan, unveiled today, is a stunning shift from a policy announced on 2 May that aimed to limit how much money a researcher could get from the agency.
NIH scraps plans for cap on research grants [Nature] Agency plans to set up a separate fund for early- to mid-career investigators to help lower average age of NIH grantees.
Launching the Next Generation Researchers Initiative to Strengthen the Biomedical Research Enterprise [NIH] We are shifting toward a bold, more focused approach to bolster support to early- and mid-career investigators while we continue to work with experts on approaches to evaluate our research portfolio. In recognition of the call for such action in the 21st Century Cures Act, we are naming this effort the Next Generation Researchers Initiative.
	6.1 Observation
More Cancers Caught in Wealthy People [HealthDay News] Affluent people may expect and demand more testing, and health systems serving them may regard offering more testing "as a good way to produce more patients and increase business," said Dr. H. Gilbert Welch and Dr. Elliott Fisher, of The Dartmouth Institute for Health Policy and Clinical Practice.
	6.10 Politiques
Colossal majority for Labour MP who fought cancer after last election [The Telegraph] The professional cellist spent significant stretches of the last Parliament being treated for breast cancer and had campaigned for remote voting for MPs after being unable to attend crucial divisions.
	6.11 Patients
When Your Personal War on Cancer Is Exhausting [NY Times] Perhaps one reason for militant cancer language relates to treatment fatigue. It takes grit to subject oneself to injurious rays, toxins and excisions, especially when they harm an existence extended for only a limited period of time.
I have a brain tumour. I'm scared it will affect my job as a surgeon [The Guardian] The consultant surgeon tells me I need surgery, there is no other choice. The tumour is too big to be treated with radiotherapy or to plan a wait and watch policy.
	6.6 Publications
OpenAIRE can form the basis for a truly public European Open Access Platform [LSE Impact Blog] OpenAIRE has built a robust infrastructure to support the interoperability of repositories, publishers, research information systems, funder information and more.
Text-mining tool seeks out ‘hidden data’ [Nature] Forgotten to free your data? A tool called Wide-Open can search out instances of locked online research data sets that are supposed to be public — and it has already flagged hundreds of such instances in genetics research, according to a study published in PLoS Biology on 8 June.
	6.9 Controverses
FBI raids offices of lab that pays doctors to promote genetic tests [STAT] A regulatory loophole allows many genetic testing companies, including Proove, to operate without government oversight on the medical value of their tests.